These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18041893)

  • 1. Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome.
    Hueser CN; Patel AJ
    Pharmacotherapy; 2007 Dec; 27(12):1759-62. PubMed ID: 18041893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interstitial lung disease associated with azacitidine use: a case report.
    Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR
    Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine-Induced Pericarditis: A Case Series.
    Newman M; Malla M; Gojo I
    Pharmacotherapy; 2016 Apr; 36(4):443-8. PubMed ID: 26940554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine-associated acute interstitial pneumonitis.
    Kuroda J; Shimura Y; Mizutani S; Nagoshi H; Kiyota M; Chinen Y; Maegawa S; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
    Intern Med; 2014; 53(11):1165-9. PubMed ID: 24881742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine-Induced Interstitial Pneumonitis.
    Verriere B; Ferreira V; Denis E; Zahreddine K; Deletie E; Quinsat D; Re D
    Am J Ther; 2016; 23(5):e1205-8. PubMed ID: 26371947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azacitidine adverse effects in patients with myelodysplastic syndromes.
    San Miguel Amigo L; Franco Osorio R; Mercadal Vilchez S; Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():6-11. PubMed ID: 21688207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide-induced interstitial lung disease.
    Chen Y; Kiatsimkul P; Nugent K; Raj R
    Pharmacotherapy; 2010 Mar; 30(3):325. PubMed ID: 20180616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome.
    Adams CD; Szumita PM; Baroletti SA; Lilly CM
    Pharmacotherapy; 2005 May; 25(5):765-8. PubMed ID: 15899739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan.
    Hayashi M; Takayasu H; Tada M; Yamazaki Y; Tateno H; Tazawa S; Wakabayashi A; Iwasaki T; Tsuchiya Y; Yamashita J; Takeda N; Tomita S; Mori H; Kokubu F
    Intern Med; 2012; 51(17):2411-5. PubMed ID: 22975559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of azacitidine: onset, duration, and treatment.
    Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():1-5. PubMed ID: 21688206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine. Poor-prognosis myelodysplasia: promising, but more data needed.
    Prescrire Int; 2011 Feb; 20(113):40. PubMed ID: 21488589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
    Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
    J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome.
    Makita S; Munakata W; Watabe D; Maeshima AM; Taniguchi H; Toyoda K; Yamauchi N; Fukuhara S; Maruyama D; Kobayashi Y; Tobinai K
    J Int Med Res; 2017 Apr; 45(2):886-893. PubMed ID: 28415946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome.
    Nair GB; Charles M; Ogden L; Spiegler P
    Respir Care; 2012 Apr; 57(4):631-3. PubMed ID: 22005027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atraumatic splenic rupture in patients with myelodysplastic syndromes: report of a case occurred during treatment with 5-azacitidine and review of the literature.
    Forghieri F; Morselli M; Leonardi G; Potenza L; Bonacorsi G; Coluccio V; Paolini A; Maccaferri M; Colaci E; Fantuzzi V; Bigliardi S; Zaldini P; Riva G; Barozzi P; Leonardi L; Rossi A; Marasca R; Narni F; Luppi M
    Leuk Res; 2012 Mar; 36(3):e52-6. PubMed ID: 22172466
    [No Abstract]   [Full Text] [Related]  

  • 18. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 19. Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report.
    Goo K; Uy R; Roswarski J
    J Oncol Pharm Pract; 2019 Jul; 25(5):1248-1252. PubMed ID: 29933727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics.
    Turturro F; Leary C; Stephens J; Veillon D; Lowery-Nordberg M
    J Clin Oncol; 2010 Aug; 28(22):e380-1. PubMed ID: 20458054
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.